New evidence on drugs to help smokers quit

shutterstock_36041908

Some readers will be aware that the Mental Elf is no loner.  I have a number of elfin cousins who also run websites that help busy professionals keep up to date with the latest research, policy and guidance in their field. One such site is The Lifestyle Elf, and she has written a blog recently that will be of interest to mental health professionals:

What takes around seven seconds to reach your brain from your mouth? Nicotine. Once there, it alters a number of chemicals, producing both calming and stimulating effects. It is, of course, highly addictive and the body’s nervous system becomes dependent on its effects. Withdrawing from nicotine produces an array of unpleasant effects, ranging from low mood and anxiety to constipation and tiredness.

There is a class of drugs called nicotine receptor partial agonists which may help those trying to quit, by reducing both the pain of withdrawing and the pleasure of smoking. This week an updated version of a Cochrane review has been published on the effectiveness and tolerability of some of these drugs, including cytisine, dianicline, bupropion and varenicline.  A systematic and comprehensive search yielded 24 randomised controlled trials (RCTs) suitable for inclusion. To be included, studies had to measure abstinence from smoking for at least six months. The bulk of the evidence relates to varenicline, for which there were twenty good quality trials, involving over 12,000 people. Here’s what they found:

  • Varenicline at standard dosage (1.0 mg twice a day) increased the chances of successful long-term smoking cessation by more than two-fold compared with quit attempts with no drug support
  • Varenicline at reduced dosage remained an effective aid to smoking cessation, delivering success rates similar to those achieved with nicotine replacement and bupropion, and appearing to reduce the impact of adverse events in the early weeks of treatment
  • Limited evidence suggests that varenicline may have a role to play in relapse prevention
  • The main adverse effect of varenicline was nausea but mostly at mild to moderate levels and tending to subside over time BUT there is evidence to suggest that users of varenicline may have a higher risk of serious ill effects (including psychiatric and heart problems), with rates about one-third higher than in those not using the drug, which needs to be explored in future research
  • More people quit successfully with varenicline than buproprion
  • Cytisine (2 RTCs, 973 people) was shown to be effective and affordable, with no increase in adverse effects, though quit rates were modest
  • Dianicline was no more effective than placebo in helping people to quit. Development of the drug has been discontinued.

A note on the availability of cytisine (Tabex):

Cytisine is not licensed for use as a smoking cessation aid in the European Union or in the USA, but there is increasing interest in this drug, which was developed in the 1960s in Bulgaria and is available in some eastern and central European countries. This review cites two recent studies which have highlighted its potential as an affordable drug for smoking cessation, particularly in countries with lower average incomes and where smoking cessation programmes are not supported by insurance plans or by a national health service. They also note that in New Zealand, where it is found in the seeds of the native Kowhai tree, widely used in traditional Maori healing, a large randomised trial comparing cytisine with nicotine replacement therapy is underway and results are expected next year.

Links

Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD006103. DOI: 10.1002/14651858.CD006103.pub6

Cochrane summary of this review.

Share on Facebook Tweet this on Twitter Share on LinkedIn Share on Google+
Mark as read
Create a personal elf note about this blog
Andre Tomlin

Andre Tomlin

André Tomlin is an Information Scientist with 20 years experience working in evidence-based healthcare. He's worked in the NHS, for Oxford University and since 2002 as Managing Director of Minervation Ltd, a consultancy company who do clever digital stuff for charities, universities and the public sector. Most recently André has been the driving force behind the Mental Elf and the National Elf Service; an innovative digital platform that helps professionals keep up to date with simple, clear and engaging summaries of evidence-based research. André is a Trustee at the Centre for Mental Health and an Honorary Research Fellow at University College London Division of Psychiatry. He lives in Bristol with his wife, dog and three little elflings.

More posts - Website

Follow me here –